Alzheimer's Disease (AD) and related dementias represent one of the most urgent unmet medical needs in neuroscience. Despite significant public and private investment, progress toward effective disease-modifying therapies has been frustratingly slow, in part due to the lack of human-relevant preclinical models that capture the full complexity of neuroinflammation. Microglia—the resident immune cells of the central nervous system—play a critical role in AD pathology yet are absent from most standard in vitro organoid systems.

To address this gap, 28bio has developed CNS-3D Inflammatory Organoids: a scalable, human iPSC-derived cortical organoid platform that integrates microglia to enable a neuroinflammatory component critical for modeling Alzheimer’s disease. In this poster, we describe the generation and characterization of these organoids, demonstrate stimulus-specific inflammatory phenotypes, and present pilot data on amyloid beta (Aβ) oligomer-induced functional decline.

These data establish CNS-3D Inflammatory Organoids as a human-relevant, inducible neuroinflammatory platform for modeling Alzheimer’s disease progression and evaluating candidate therapeutics.